Provided by Tiger Trade Technology Pte. Ltd.

PTC Therapeutics

66.13
-0.8700-1.30%
Post-market: 66.130.00000.00%16:57 EDT
Volume:1.04M
Turnover:68.76M
Market Cap:5.47B
PE:8.50
High:67.60
Open:67.43
Low:65.80
Close:67.00
52wk High:87.50
52wk Low:35.95
Shares:82.77M
Float Shares:72.98M
Volume Ratio:0.93
T/O Rate:1.42%
Dividend:- -
Dividend Rate:- -
EPS(TTM):7.78
EPS(LYR):7.78
ROE:-7740.12%
ROA:23.26%
PB:-26.66
PE(LYR):8.50

Loading ...

A Look At PTC Therapeutics (PTCT) Valuation As Shares Reflect Mixed Recent Returns

Simply Wall St.
·
Mar 27

PTC Therapeutics files initial beneficial ownership statement; Director Jessica Caroline Chutter reports no securities beneficially owned

Reuters
·
Mar 27

PTC Therapeutics Adds Veteran Banker to Board

TIPRANKS
·
Mar 25

BRIEF-Ptc Therapeutics Appoints Biotech Banking Pioneer Jessica Chutter To Board Of Directors

Reuters
·
Mar 25

PTC Therapeutics appoints Jessica Chutter to board; Chutter retires from Morgan Stanley after 40 years

Reuters
·
Mar 25

PTC Therapeutics Appoints Biotech Banking Pioneer Jessica Chutter to Board of Directors

THOMSON REUTERS
·
Mar 25

PTC Therapeutics grants stock options for 14,550 shares at USD 68.56 per share

Reuters
·
Mar 14

BUZZ-Street View: Tough path ahead for uniQure after FDA setback on Huntington's therapy

Reuters
·
Mar 03

PTC Therapeutics EVP and CLO Mark Elliott Boulding Disposes of Common Shares

Reuters
·
Feb 24

PTC Therapeutics to Present at TD Cowen, Leerink, and Barclays Global Healthcare Conferences

Reuters
·
Feb 23

Morgan Stanley Lifts Price Target on PTC Therapeutics to $92 From $90, Keeps Overweight Rating

MT Newswires Live
·
Feb 23

J.P. Morgan Keeps Their Buy Rating on PTC Therapeutics (PTCT)

TIPRANKS
·
Feb 23

PTC Therapeutics : Morgan Stanley Raises Target Price to $92.00 From $90.00

THOMSON REUTERS
·
Feb 23

Barclays Keeps Their Buy Rating on PTC Therapeutics (PTCT)

TIPRANKS
·
Feb 23

Stock Track | PTC Therapeutics Plummets 5.14% Intraday After Earnings Miss and RBC Price Target Cut

Stock Track
·
Feb 20

RBC Cuts Price Target on PTC Therapeutics to $82 From $87, Keeps Sector Perform Rating

MT Newswires Live
·
Feb 20

PTC Therapeutics Is Maintained at Buy by B of A Securities

Dow Jones
·
Feb 20

RBC Capital Keeps Their Hold Rating on PTC Therapeutics (PTCT)

TIPRANKS
·
Feb 20

Bank of America Securities Reaffirms Their Buy Rating on PTC Therapeutics (PTCT)

TIPRANKS
·
Feb 20

Sephience-Led Growth, Global Expansion, and Robust Pipeline Underpin Buy Rating on PTC Therapeutics

TIPRANKS
·
Feb 20